Ra Pharmaceuticals Inc (NASDAQ:RARX) has received a consensus rating of “Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $38.70.
Several analysts recently commented on the company. Raymond James upped their target price on Ra Pharmaceuticals from $39.00 to $44.00 and gave the company a “strong-buy” rating in a report on Friday, March 8th. BidaskClub cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 11th. Zacks Investment Research cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. BMO Capital Markets set a $33.00 target price on Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 8th. Finally, Svb Leerink assumed coverage on Ra Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $33.00 target price on the stock.
Shares of RARX stock opened at $21.26 on Monday. Ra Pharmaceuticals has a one year low of $8.27 and a one year high of $27.68. The company has a market capitalization of $899.36 million, a P/E ratio of -10.32 and a beta of 0.80. The company has a current ratio of 20.10, a quick ratio of 20.10 and a debt-to-equity ratio of 0.02.
Institutional investors have recently bought and sold shares of the business. RA Capital Management LLC boosted its stake in Ra Pharmaceuticals by 26.1% during the fourth quarter. RA Capital Management LLC now owns 4,858,260 shares of the company’s stock valued at $33,963,000 after buying an additional 1,006,452 shares during the last quarter. BlackRock Inc. increased its holdings in Ra Pharmaceuticals by 29.0% during the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock worth $48,142,000 after purchasing an additional 595,328 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in Ra Pharmaceuticals by 16.5% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 1,024,000 shares of the company’s stock worth $22,939,000 after purchasing an additional 145,000 shares during the period. Sectoral Asset Management Inc increased its holdings in Ra Pharmaceuticals by 129.3% during the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock worth $14,553,000 after purchasing an additional 450,900 shares during the period. Finally, Vanguard Group Inc. boosted its position in Ra Pharmaceuticals by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 739,337 shares of the company’s stock valued at $13,374,000 after acquiring an additional 61,929 shares in the last quarter. Hedge funds and other institutional investors own 94.97% of the company’s stock.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.